Great Tree Pharmacy Co., Ltd. AI Stock Analysis
Great Tree Pharmacy Co., Ltd. (6469) AI Stock Analysis
Great Tree Pharmacy Co., Ltd.
(TPEx:6469)
The score is primarily restrained by declining profitability, rising leverage, weaker cash-flow coverage, and technically weak price momentum. A reasonable P/E and high dividend yield provide meaningful support, but they do not fully offset the financial and technical risks.
Great Tree Pharmacy Co., Ltd. (6469) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 9.03B
- Dividend Yield
- 5.49%
- Average Volume (3M)
- 399.71K
- Price to Earnings (P/E)
- 16.6
- Beta (1Y)
- 0.13
- Revenue Growth
- 4.00%
- EPS Growth
- -25.06%
- Country
- TW
- Employees
- 446
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Great Tree Pharmacy Co., Ltd. Business Overview & Revenue Model
Company Description
Great Tree Pharmacy Co., Ltd. is a Taiwanese enterprise that operates an extensive chain of pharmacies throughout the island nation. These retail outlets offer a broad selection of goods, including prescription and over-the-counter medications, nutri...
Great Tree Pharmacy Co., Ltd. Financial Statement Overview
Summary
Revenue and gross margin improved, and the business remains profitable with positive operating and free cash flow. However, declining operating profit, net income, and margins, alongside higher leverage and weaker cash-flow coverage, limit the score.
Income Statement
65PositiveBalance Sheet
55NeutralCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.02B | 18.90B | 17.27B | 16.14B | 14.56B | 11.28B |
| Gross Profit | 5.43B | 5.42B | 4.84B | 4.49B | 4.01B | 2.94B |
| EBITDA | 1.52B | 1.71B | 1.71B | 1.60B | 1.54B | 1.04B |
| Net Income | 515.77M | 600.42M | 680.77M | 666.05M | 700.07M | 407.42M |
Balance Sheet | ||||||
| Total Assets | 14.02B | 13.76B | 12.13B | 10.77B | 10.12B | 7.39B |
| Cash, Cash Equivalents and Short-Term Investments | 2.53B | 2.54B | 2.23B | 2.16B | 2.48B | 1.33B |
| Total Debt | 6.44B | 7.07B | 6.00B | 5.14B | 5.13B | 3.83B |
| Total Liabilities | 10.28B | 9.76B | 8.48B | 7.42B | 7.49B | 5.44B |
| Stockholders Equity | 3.67B | 3.92B | 3.60B | 3.28B | 2.60B | 1.93B |
Cash Flow | ||||||
| Free Cash Flow | 623.39M | 787.01M | 779.64M | 564.03M | 910.93M | 823.18M |
| Operating Cash Flow | 965.15M | 1.17B | 1.14B | 890.33M | 1.23B | 1.08B |
| Investing Cash Flow | -684.52M | -880.71M | -881.37M | -416.53M | -465.58M | -268.43M |
| Financing Cash Flow | -597.02M | -409.63M | -499.08M | -795.84M | 389.10M | -336.57M |
Great Tree Pharmacy Co., Ltd. Peers Comparison
Overall Rating
TW:120370Outperform
TW:679068.2Neutral
TW:653467Neutral
TW:843662Neutral
TW:646957Neutral
TW:170243Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | TWD 10.47B | 20.50 | ― | 2.33% | -13.42% | 12.83% | |
| 68Neutral | TWD 9.84B | 11.95 | ― | 7.17% | -3.83% | 17.72% | |
| 67Neutral | TWD 8.35B | 15.04 | ― | 6.23% | 6.31% | 31.07% | |
| 62Neutral | TWD 10.68B | 10.48 | ― | 6.58% | -3.82% | 2.23% | |
| 57Neutral | TWD 9.20B | 16.59 | ― | 5.49% | 4.00% | -25.06% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 43Neutral | TWD 7.65B | 168.06 | ― | 5.29% | -0.31% | -90.22% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6469 | Great Tree Pharmacy Co., Ltd. | 57.50 | -37.07 | -39.20% | |
| TW:1203 | Ve Wong Corporation | 42.85 | 4.34 | 11.27% | |
| TW:1702 | Namchow Holdings Co., Ltd. | 30.25 | -6.52 | -17.73% | |
| TW:6534 | CH Biotech R&D Co., Ltd. | 85.20 | -3.49 | -3.93% | |
| TW:6790 | Yuen Foong Yu Consumer Products Co., Ltd. | 36.95 | 1.43 | 4.03% | |
| TW:8436 | TCI Co., Ltd. | 91.40 | -22.40 | -19.68% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
